EUVIMEDEUVIMED entdecken
Crossref

Usefulness of lipid-lowering therapy in stabilizing vulnerable atherosclerotic plaque: Focus on intraplaque neovascularization

Hyungseop Kim iD, Hee-Jeong Lee, In-Cheol Kim, Yun-Kyeong Cho, Cheol-Hyun Lee

Vascular Medicine · 2026

DOI: 10.1177/1358863x251405282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vascular Medicine, 2026. Verfasst von Hyungseop Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Cardiology, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, R…. Hauptthemen laut MEDLINE: Rosuvastatin Calcium, Plaque, Atherosclerotic, Neovascularization, Pathologic, Ezetimibe. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intraplaque neovascularization (IPN) is related to the progression of atherosclerotic plaque. The impact of lipid-lowering therapy (LLT) on IPN regression is unclear. We aimed to investigate the efficacy of LLT to regress IPN.

Methods

Between April 2022 and July 2024, 56 patients who had percutaneous coronary intervention (PCI) for angina or acute coronary syndrome and had not used LLT for at least 6 months were included. Contrast-enhanced ultrasound (CEUS) of the carotid artery was performed to evaluate IPN and intima–media thickness (IMT) within 7 days post-PCI. They received a combination of rosuvastatin 10 mg and ezetimibe 10 mg starting after PCI and continued for 1 year. Lipid profile changes and contrast enhancement were evaluated at baseline and 1 year later. The primary outcome was IPN regression, defined as the downgrade changes in the enhancement of contrast in atherosclerotic plaque at follow up.

Results

The mean follow up was 12.6 ± 0.9 months. The IPN regression rate was 41%. Patients achieving IPN regression initially had a higher low-density lipoprotein-cholesterol (LDL-C) level and a greater percentage reduction in LDL-C. Whereas lipid profiles change significantly, no notable alterations were observed in IMT, plaque thickness, or plaque density. However, a 59% reduction in LDL-C was identified as the optimal cutoff level for IPN regression (OR 0.86, 95% CI 0.75–0.96).

Conclusion

LLT, such as rosuvastatin 10 mg with ezetimibe 10 mg, may effectively inhibit IPN by reducing LDL-C levels, providing a promising treatment option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rosuvastatin CalciumPlaque, AtheroscleroticNeovascularization, PathologicEzetimibeCarotid Artery DiseasesPercutaneous Coronary InterventionCoronary Artery DiseaseHydroxymethylglutaryl-CoA Reductase InhibitorsAcute Coronary SyndromeHumansFemaleMaleAgedTreatment OutcomeMiddle AgedTime FactorsCarotid Intima-Media ThicknessBiomarkersUltrasonography, Carotid ArteriesCholesterol, LDL

Stichwörter der Autor:innen

carotid artery diseasecontrast-enhanced ultrasoundneovascularizationplaquevascular imaging/diagnostics

Substanzen

Rosuvastatin CalciumEzetimibeBiomarkersHydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDL

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Cardiology, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea.

ORCID-Profile: Hyungseop Kim

Zitieren

APA

Kim, H., Lee, H. J., Kim, I. C., Cho, Y. K., & Lee, C. H. (2026). Usefulness of lipid-lowering therapy in stabilizing vulnerable atherosclerotic plaque: Focus on intraplaque neovascularization. Vascular Medicine. https://doi.org/10.1177/1358863x251405282

Vancouver

Kim H, Lee HJ, Kim IC, Cho YK, Lee CH. Usefulness of lipid-lowering therapy in stabilizing vulnerable atherosclerotic plaque: Focus on intraplaque neovascularization. Vascular Medicine. 2026. doi:10.1177/1358863x251405282

BibTeX
@article{Kim2026,
  author = {Kim, Hyungseop and Lee, Hee-Jeong and Kim, In-Cheol and Cho, Yun-Kyeong and Lee, Cheol-Hyun},
  title = {Usefulness of lipid-lowering therapy in stabilizing vulnerable atherosclerotic plaque: Focus on intraplaque neovascularization},
  journal = {Vascular Medicine},
  year = {2026},
  doi = {10.1177/1358863x251405282}
}
Kostenlos starten →